Deucravacitinib for treating moderate to severe plaque psoriasis

  • Technology appraisal guidance
  • TA907
  • Published: 
Download guidance (PDF)

2 Information about deucravacitinib

Marketing authorisation indication

2.1 Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is indicated for 'the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for deucravacitinib.

Price

2.3 The list price of deucravacitinib is £690 per 28‑tablet pack (excluding VAT; company submission).

2.4 The company has a commercial arrangement. This makes deucravacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.